We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Stephan Moll MD

Stephan Moll MD

Professor of Medicine, Division of Hematology, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Stephan Moll, MD, received his medical degree from Freiburg University, Germany, including a one year of clinical training in London (Hammersmith Hospital and Institute of Neurology at Queens Square), and performed a pathology residency at the Institute of Pathology, University of Aachen, Germany. He completed an internship and residency in Internal Medicine and a Hematology-Oncology fellowship at Duke University Medical Center, North Carolina, and a one-year Clinical Coagulation fellowship at the University of North Carolina (UNC), Chapel Hill. Dr Moll has been a faculty member at the University of North Carolina in the Department of Medicine and the Division of Hematology-Oncology since 1999, now at the rank of full professor.

His clinical interest is coagulation and classical hematology, with a particular focus on thrombosis and anticoagulation. Dr Moll’s research interests include clinical trials on new anticoagulants and better use of established anticoagulants. He takes a special interest in clinical-medical education of healthcare professionals, patients and the public, and is a cofounder of the UNC Blood Clot Education Program Clot Connect, at www.clotconnect.org. His four main professional goals for the next 5-10 years are to (1) enhance national and local patient and health care provider education activities on venous thromboembolism, (2) continue to build an “Athletes and Blood Clot Program”, (3) support trainees in their career development in the field of coagulation/hematology, (4) identify the etiology and best treatment of Livedoid Vasculopathy through collaborative research.


Dr. Moll has no relevant disclosures.